SEC Form 4 · accession 0001209191-17-046036

Sarepta Therapeutics, Inc. · SRPT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, General Counsel

Period of report

Jul 20, 2017

Accepted (ET)

Jul 21, 2017 · 9:46 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000873303

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jul 20, 2017	M	19,056	$13.71	A	41,357	D
Common Stock^F1	Jul 20, 2017	S	19,056	$41.00	D	22,301	D
Common Stock^F1	Jul 20, 2017	M	5,944	$13.71	A	28,245	D
Common Stock^F1	Jul 20, 2017	S	5,944	$41.00	D	22,301	D
Common Stock	Jul 21, 2017	M	324	$13.71	A	22,625	D
Common Stock	Jul 21, 2017	M	676	$23.85	A	23,301	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Options (right to buy)^F1	$13.71	Jul 20, 2017	M	19,056	D	Feb 28, 2017	Feb 28, 2026	Common Stock	19,056	10,527	D
Non-Qualified Stock Options (right to buy)^F1	$13.71	Jul 20, 2017	M	5,944	D	Feb 28, 2017	Feb 28, 2026	Common Stock	5,944	19,146	D
Incentive Stock Option (right to buy)^F2	$13.71	Jul 21, 2017	M	324	D	Feb 28, 2017	Feb 28, 2026	Common Stock	324	93	D
Incentive Stock Option (right to buy)^F3	$23.85	Jul 21, 2017	M	676	D	Nov 5, 2013	Nov 5, 2022	Common Stock	676	15,092	D

F1This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
F2Half of the options begin vesting in the event the FDA provides marketing approval for eteplirsen as of the applicable PDUFA date and the other half of the options begin vesting in the event Sarepta files a Marketing Authorization Application with the EMEA prior to December 31, 2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vests immediately upon achievement of the performance condition (25% of the total Performance-Based Options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total Performance-Based Options granted) vests over four years with 25% of these remaining options vesting on the first year anniversary of the grant date and 1/48th of these remaining options vesting monthly thereafter.
F325% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire.